Aerovate Therapeutics, Inc.(AVTE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

AVTE Aerovate Therapeutics, Inc.

Closed 11-07 16:00:00 EST

2.74

-0.02

-0.72%

盘后2.67

-0.07-2.55%

19:02 EST

High2.80	Low2.71	Vol315.03K
Open2.78	D1 Closing2.76	Amplitude3.26%
Mkt Cap79.10M	Tradable Cap32.46M	Total Shares28.87M
T/O866.56K	T/O Rate2.66%	Tradable Shares11.85M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"AVTE","market":"US","secType":"STK","nameCN":"Aerovate Therapeutics, Inc.","latestPrice":2.74,"timestamp":1731013200000,"preClose":2.76,"halted":0,"volume":315029,"hourTrading":{"tag":"盘后","latestPrice":2.67,"preClose":2.74,"latestTime":"19:02 EST","volume":2361,"amount":6422.2915,"timestamp":1731024130298},"delay":0,"floatShares":11847155,"shares":28867711,"eps":-3.126263,"marketStatus":"Closed","change":-0.02,"latestTime":"11-07 16:00:00 EST","open":2.78,"high":2.8,"low":2.71,"amount":866562.8714599999,"amplitude":0.032609,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.126263,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1731056400000},"marketStatusCode":5,"adr":0,"listingDate":1625025600000,"exchange":"NASDAQ","adjPreClose":2.76,"preHourTrading":{"tag":"盘前","latestPrice":2.69,"preClose":2.76,"latestTime":"09:28 EST","volume":1655,"amount":4445.371375,"timestamp":1730989695222},"postHourTrading":{"tag":"盘后","latestPrice":2.67,"preClose":2.74,"latestTime":"19:02 EST","volume":2361,"amount":6422.2915,"timestamp":1731024130298},"volumeRatio":0.042151,"impliedVol":0.8368,"impliedVolPercentile":0.203},"requestUrl":"/m/hq/s/AVTE","defaultTab":"news","newsList":[{"id":"2480348381","title":"M&A deals roundup: AbbVie, Blackstone, Take-Two Interactive and more","url":"https://stock-news.laohu8.com/highlight/detail?id=2480348381","media":"seekingalpha","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480348381?lang=en_us&edition=fundamental","pubTime":"2024-11-03 03:34","pubTimestamp":1730576040,"startTime":"0","endTime":"0","summary":"Edwin Tan  Companies that grabbed headlines in the deals space include: AbbVie  has agreed to acquire all outstanding equity of neuroscience-focused biotech Aliada Therapeutics for $1.4B in cash. Stericycle  disclosed that all the closing conditions for its planned $ 62-a-share sale to Waste Management  have been received. Maersk  CEO Vincent Clerc said the shipping and logistics company won't be participating in the GXO Logistics  sales process. Blackstone  is the mystery investor who bid for a $7 billion minority stake in Roger Communication Inc.'s  cell phone infrastructure business. Siemens   agreed to buy Altair Engineering  for $113 a share in cash, or a total deal value of $10.6 billion, the companies announced Wednesday. Take-Two Interactive  ticks higher on report it's in talks to sell adtech division. Cleveland-Cliffs  said it won the final approvals needed for its planned $2.5 billion purchase of Stelco  and the deal is scheduled to close on Friday. GSK  has agreed to acquir","market":"fut","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1420639945/image_1420639945.jpg?io=getty-c-w750","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1420639945/image_1420639945.jpg?io=getty-c-w750"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4233378-ma-deals-roundup-abbvie-blackstone-take-two-interactive-and-more","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_trending_news","symbols":["LU1815336091.USD","NQmain","ALTR","GLYC","SIEGY","AVTE","LU0175139822.USD","TRUE","IE0009355771.USD","RPD","LU0689626769.HKD","QID","LU0203345920.USD","SRCL","LU0640476718.USD","GXO","GSK","LU0052756011.USD","BK4007","GSK.UK","LU0061475181.USD","TQQQ","LU1939255532.USD","ABBV",".IXIC","AMKBY","CLF","LU0965509101.SGD","PSQ","BX","STZHF","MNQmain","BK4021","SQQQ","LU0211327993.USD","LU0795875169.SGD","BK4006","BK4532","LU2211814178.USD","TTWO","LU0069063385.USD","SMAWF","QLD","RCI","WM","PARA","LU2106854487.HKD","LU0057025933.USD","LU2298064838.USD"],"gpt_icon":1},{"id":"2479380570","title":"BRIEF-Aerovate Therapeutics - Exchange Ratio Assumes  Valuation For Aerovate Of $8.0 Million And  Valuation For Jade Of $175.0 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2479380570","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479380570?lang=en_us&edition=fundamental","pubTime":"2024-10-31 21:55","pubTimestamp":1730382943,"startTime":"0","endTime":"0","summary":"Oct 31  - Aerovate Therapeutics Inc   :   * AEROVATE THERAPEUTICS - EXCHANGE RATIO ASSUMES  VALUATION FOR AEROVATE OF $8.0 MILLION AND  VALUATION FOR JADE OF $175.0 MILLION   * AEROVATE THERAPEUTICS - UPON TERMINATION OF DEAL UNDER SPECIFIED CIRCUMSTANCES, CO MAY BE REQUIRED TO PAY JADE TERMINATION FEE OF $2.3 MILLION   * AEROVATE THERAPEUTICS - UPON TERMINATION OF DEAL UNDER CERTAIN CIRCUMSTANCES, JADE MAY BE REQUIRED TO PAY CO TERMINATION FEE OF $5.3 MILLIONSource text:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AVTE","BK4539","LENZ"],"gpt_icon":0},{"id":"2479877110","title":"Aerovate Therapeutics - Exchange Ratio Assumes  Valuation for Aerovate of $8.0 Million and  Valuation for Jade of $175.0 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2479877110","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479877110?lang=en_us&edition=fundamental","pubTime":"2024-10-31 21:33","pubTimestamp":1730381584,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241031:nFWN3M719X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4139","AVTE"],"gpt_icon":0},{"id":"2479808704","title":"Aerovate Therapeutics - Upon Termination of Deal Under Specified Circumstances, Co May Be Required to Pay Jade Termination Fee of $2.3 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2479808704","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479808704?lang=en_us&edition=fundamental","pubTime":"2024-10-31 21:33","pubTimestamp":1730381584,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241031:nFWN3M719X:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","AVTE","BK4539"],"gpt_icon":0},{"id":"2479082945","title":"Aerovate climbs on all-stock merger deal with Jade","url":"https://stock-news.laohu8.com/highlight/detail?id=2479082945","media":"seekingalpha","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479082945?lang=en_us&edition=fundamental","pubTime":"2024-10-31 20:47","pubTimestamp":1730378822,"startTime":"0","endTime":"0","summary":"Maksim LabkouskiAerovate Therapeutics  added ~24% in the pre-market on Thursday after the company agreed to merge with privately held biotech Jade Biosciences in an all-stock transaction. Concurrently, a group of healthcare investors has agreed to bring in roughly $300M in gross proceeds as part of a private investment in Jade in support of the merger. The deal is expected to close in H1 2025. Per the terms, Aerovate  shareholders are expected to own nearly 2% of the combined entity, which will trade on Nasdaq under the ticker symbol “JBIO” and operate as Jade Biosciences under the leadership of Jade’s current CEO, Tom Frohlich. The combined entity is expected to focus on Jade’s pipeline of biologics which includes an experimental antibody therapy named JADE-001, targeted at the kidney disorder, IgA nephropathy.","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1347295696/image_1347295696.jpg?io=getty-c-w750","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1347295696/image_1347295696.jpg?io=getty-c-w750"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4228395-aerovate-stock-rises-on-all-stock-merger-deal","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_trending_news","symbols":[".IXIC","PSQ","QID","NQmain","SQQQ","AVTE","TQQQ","MNQmain","BK4139","QLD","BK4539"],"gpt_icon":1},{"id":"2479208944","title":"Aerovate to Merge With Jade Biosciences, Pursue Kidney Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2479208944","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479208944?lang=en_us&edition=fundamental","pubTime":"2024-10-31 20:40","pubTimestamp":1730378400,"startTime":"0","endTime":"0","summary":"Aerovate Therapeutics agreed to merge with privately held Jade Biosciences in an all-stock transaction, forming a company focused on a kidney-disease treatment and other products.After the merger, the company will trade as Jade Biosciences on the Nasdaq Composite under the ticker symbol JBIO. It will seek to develop Jade-001, a treatment for kidney condition IgA nephropathy, among other Jade drug candidates.Jade was launched in August, the fourth company based on assets developed by Paragon Therapeutics. Jade has secured $300 million in backing for the merger from an investment consortium led by money managers Fairmount, Venrock Healthcare Capital and another unnamed firm. Prior to closing, Aerovate intends to declare a dividend, distributing cash of an estimated $65 million.The merged biotech companies will have enough cash on hand to fund operations through 2027 and advance JADE-001 to initial clinical proof-of-concept.In July, Aerovate had pledged to pursue strategic alternatives fo","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVTE","BK4539","BK4139"],"gpt_icon":0},{"id":"2479861704","title":"BRIEF-Aerovate Therapeutics And Jade Biosciences Announce Merger Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2479861704","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479861704?lang=en_us&edition=fundamental","pubTime":"2024-10-31 19:07","pubTimestamp":1730372825,"startTime":"0","endTime":"0","summary":"Oct 31  - Aerovate Therapeutics Inc   :   * AEROVATE THERAPEUTICS AND JADE BIOSCIENCES ANNOUNCE MERGER AGREEMENT   * AEROVATE THERAPEUTICS INC - JADE SECURES $300 MILLION IN PRIVATE INVESTMENT   * AEROVATE THERAPEUTICS INC - STOCKHOLDERS TO OWN 1.6% OF COMBINED COMPANY   * AEROVATE THERAPEUTICS INC - TOM FROHLICH TO LEAD COMBINED COMPANY AS CEO   * AEROVATE THERAPEUTICS INC - TO DECLARE $65 MILLION CASH DIVIDEND TO STOCKHOLDERSSource text:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AVTE","BK4539","LENZ"],"gpt_icon":0},{"id":"2479701665","title":"Aerovate Therapeutics and Jade Biosciences Announce Merger Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2479701665","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479701665?lang=en_us&edition=fundamental","pubTime":"2024-10-31 19:00","pubTimestamp":1730372402,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241031:nTUAC4Z8T5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4139","AVTE"],"gpt_icon":0},{"id":"2479701148","title":"Aerovate Therapeutics Inc - Tom Frohlich to Lead Combined Company as CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2479701148","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479701148?lang=en_us&edition=fundamental","pubTime":"2024-10-31 19:00","pubTimestamp":1730372402,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241031:nTUAC4Z8T5:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","AVTE","BK4139"],"gpt_icon":0},{"id":"2479570110","title":"Aerovate Therapeutics Inc - to Declare $65 Million Cash Dividend to Stockholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2479570110","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479570110?lang=en_us&edition=fundamental","pubTime":"2024-10-31 19:00","pubTimestamp":1730372402,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241031:nTUAC4Z8T5:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","AVTE","BK4139"],"gpt_icon":0},{"id":"2479136701","title":"Aerovate Therapeutics Inc - Stockholders to Own 1.6% of Combined Company","url":"https://stock-news.laohu8.com/highlight/detail?id=2479136701","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479136701?lang=en_us&edition=fundamental","pubTime":"2024-10-31 19:00","pubTimestamp":1730372402,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241031:nTUAC4Z8T5:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AVTE","BK4539","BK4139"],"gpt_icon":0},{"id":"2479070115","title":"Aerovate Therapeutics Inc - Jade Secures $300 Million in Private Investment","url":"https://stock-news.laohu8.com/highlight/detail?id=2479070115","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479070115?lang=en_us&edition=fundamental","pubTime":"2024-10-31 19:00","pubTimestamp":1730372402,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241031:nTUAC4Z8T5:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4139","AVTE"],"gpt_icon":0},{"id":"2479070267","title":"Aerovate Therapeutics and Jade Biosciences Announce Merger Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2479070267","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479070267?lang=en_us&edition=fundamental","pubTime":"2024-10-31 19:00","pubTimestamp":1730372400,"startTime":"0","endTime":"0","summary":"Merger to create a company focused on advancing Jade Biosciences’ portfolio of novel therapies that aim to redefine the standard of care for patients with autoimmune diseases. Jade Biosciences, the fourth company founded on assets licensed from Paragon Therapeutics, expects to initiate a clinical trial for JADE-001 in the second half of 2025. Approximately $300 million raised to date, including anticipated proceeds from an oversubscribed pre-closing private financing, expected to fund operations through 2027. Tom Frohlich, Chief Executive Officer of Jade, commented: “Jade is focused on developing breakthrough treatments for autoimmune diseases, including JADE-001, which modulates plasma cell survival and immunoglobulin production, and which we plan to initially develop for the treatment of IgA nephropathy. As the fourth antibody therapeutics venture founded on assets licensed from Paragon Therapeutics, a leader in antibody d","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/X2YQ7k7nWFbp3ZK5JpmsJw--~B/aD02NzI7dz0xODAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/f3664c45928c46deca5f70bd7fefe5be","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/X2YQ7k7nWFbp3ZK5JpmsJw--~B/aD02NzI7dz0xODAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/f3664c45928c46deca5f70bd7fefe5be"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aerovate-therapeutics-jade-biosciences-announce-110000878.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4539","CEO","LENZ","AVTE"],"gpt_icon":0},{"id":"2474064770","title":"Aerovate Therapeutics Board Member Maha Katabi Resigns","url":"https://stock-news.laohu8.com/highlight/detail?id=2474064770","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2474064770?lang=en_us&edition=fundamental","pubTime":"2024-10-11 05:28","pubTimestamp":1728595701,"startTime":"0","endTime":"0","summary":"Aerovate Therapeutics ( ($AVTE) ) has provided an announcement. Maha Katabi, Ph.D., has resigned from Aerovate Therapeutics’ board of directors and...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/aerovate-therapeutics-board-member-maha-katabi-resigns?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/aerovate-therapeutics-board-member-maha-katabi-resigns?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","AVTE","LENZ","BK4539"],"gpt_icon":0},{"id":"2466423288","title":"Tracking Baker Brothers Portfolio - Q2 2024 Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2466423288","media":"seekingalpha","labels":["analysis"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466423288?lang=en_us&edition=fundamental","pubTime":"2024-09-11 11:54","pubTimestamp":1726026860,"startTime":"0","endTime":"0","summary":"Baker Brothers' 13F portfolio value decreased from $7.97B to $7.83B this quarter.New stakes include Summit Therapeutics and Alkermes plc, while ACADIA Pharmaceuticals, Madrigal Pharmaceuticals, and In","market":"us","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1160060870/image_1160060870.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1160060870/image_1160060870.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4720332-tracking-baker-brothers-portfolio-q2-2024-update","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"analysis","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["IGMS","TRDA","AKRO","VTVT","ATHA","RYTM","SGMT","GLUE","AVTE","MDGL","ARGX","LU0234570918.USD","KNSA","TCRX","ABCL","HOOK","ALKS","INCY","NRIX","RARE","KYMR","SMMT","ACAD","ACHL","REPL","BCYC","IE00BSNM7G36.USD","EWTX","ADAP","KALA","DNLI","BMEA","IMCR","ROIV","STOK","ALGS","KOD","BCRX","CERE","LU0256863902.USD","IE00B19Z3581.USD","OPT","RVMD","INSM","BGNE","CERS","IMTX","ABBV","TSVT"],"gpt_icon":1},{"id":"2459977980","title":"Analysts Conflicted on These Healthcare Names: Oric Pharmaceuticals (ORIC), Aerovate Therapeutics (AVTE) and McKesson (MCK)","url":"https://stock-news.laohu8.com/highlight/detail?id=2459977980","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459977980?lang=en_us&edition=fundamental","pubTime":"2024-08-13 20:01","pubTimestamp":1723550460,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Oric Pharmaceuticals (ORIC – Research Report), Aerovate Therapeut...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-oric-pharmaceuticals-oric-aerovate-therapeutics-avte-and-mckesson-mck?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-oric-pharmaceuticals-oric-aerovate-therapeutics-avte-and-mckesson-mck?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HCSG","ORIC","MCK","LU1814569148.SGD","AVTE","LU0868494708.USD","LU0048573561.USD","LU0742534661.SGD","BK4588","LU2089984988.USD","LU0251131958.USD","LU2112291526.USD","LU1057294990.SGD","BK4585","LU1430594728.SGD","LU1983260115.SGD","BK4533","LU0122379950.USD","LU2468319806.SGD","LU2324357040.USD","LU0251142724.SGD","LU1061106388.HKD","LU1023059063.AUD","BK4175","BK4139","LU1585245621.USD","BK4539","BK4137","LU0868494617.USD","LU0942090050.USD"],"gpt_icon":0},{"id":"2458910677","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2458910677","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2458910677?lang=en_us&edition=fundamental","pubTime":"2024-08-12 18:00","pubTimestamp":1723456800,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AUGX","ATAI","IBTA","EQ","RVPH","ACHV","XP","LAAC","VALN","WULF","BTM","HBM","PHI","SLRN","LUNR","STIM","HD","ONON","EYEN","CNTA","FBRX","EC","NU","CTSO","LVTX","ZVRA","CALT","AVTE","ARAY","ESPR","FLUT","LOAR","EARN","PRAX","IMOS","MNR","DERM","BLDP","OGI","XOS","URGN","VERO","VTYX","UNCY","PSFE","CCLD","PYXS","SCYX","MDAI","USPH"],"gpt_icon":0},{"id":"2449777987","title":"Aerovate Therapeutics to Explore Strategic Alternatives After Hypertension Trial Shutdown","url":"https://stock-news.laohu8.com/highlight/detail?id=2449777987","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2449777987?lang=en_us&edition=fundamental","pubTime":"2024-07-08 20:44","pubTimestamp":1720442696,"startTime":"0","endTime":"0","summary":"Aerovate Therapeutics  said Monday it will consider strategic alternatives following its announcement that it was stopping enrollment and shutting down the phase 3 portion of its Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial and the long-term extension study.The company said it sought the assistance of Wedbush PacGrow in the process of exploring alternatives, which may include an acquisition, merger, reverse merger, business combination, liquidation, or other transaction.There is no timetable for completion of the review process and there is no assurance that the process will lead to a deal, the company said.Shares of Aerovate Therapeutics were up 3.1% in premarket activity.Price: 1.6500, Change: +0.04, Percent Change: +2.48","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","AVTE"],"gpt_icon":0},{"id":"2449577795","title":"Aerovate Therapeutics to Explore Strategic Alternatives After Hypertension Trial Shutdown","url":"https://stock-news.laohu8.com/highlight/detail?id=2449577795","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2449577795?lang=en_us&edition=fundamental","pubTime":"2024-07-08 20:44","pubTimestamp":1720442696,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_live","symbols":["AVTE","BK4139","BK4539"],"gpt_icon":0},{"id":"2449774109","title":"BRIEF-Aerovate Therapeutics To Explore Strategic Alternatives","url":"https://stock-news.laohu8.com/highlight/detail?id=2449774109","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2449774109?lang=en_us&edition=fundamental","pubTime":"2024-07-08 20:15","pubTimestamp":1720440939,"startTime":"0","endTime":"0","summary":"July 8  - Aerovate Therapeutics Inc   :   * AEROVATE THERAPEUTICS TO EXPLORE STRATEGIC ALTERNATIVES   * AEROVATE THERAPEUTICS INC - TO CONDUCT STRATEGIC ALTERNATIVES REVIEW   * AEROVATE THERAPEUTICS - WEDBUSH PACGROW ENGAGED AS EXCLUSIVE ADVISORSource text for Eikon:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","AVTE"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.aerovatetx.com","stockEarnings":[{"period":"1week","weight":0.2603},{"period":"1month","weight":0.3269},{"period":"3month","weight":0.6235},{"period":"6month","weight":-0.8608},{"period":"1year","weight":-0.7745},{"period":"ytd","weight":-0.878}],"compareEarnings":[{"period":"1week","weight":0.019},{"period":"1month","weight":0.0409},{"period":"3month","weight":0.1138},{"period":"6month","weight":0.1348},{"period":"1year","weight":0.3527},{"period":"ytd","weight":0.2435}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.121433},{"month":2,"riseRate":0.666667,"avgChangeRate":0.03264},{"month":3,"riseRate":0.666667,"avgChangeRate":0.32545},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.196019},{"month":5,"riseRate":0,"avgChangeRate":-0.133359},{"month":6,"riseRate":0.666667,"avgChangeRate":-0.187689},{"month":7,"riseRate":0.75,"avgChangeRate":0.02507},{"month":8,"riseRate":0.5,"avgChangeRate":0.04806},{"month":9,"riseRate":0.5,"avgChangeRate":0.000156},{"month":10,"riseRate":0.5,"avgChangeRate":-0.027466},{"month":11,"riseRate":0.5,"avgChangeRate":0.108377},{"month":12,"riseRate":0.666667,"avgChangeRate":0.285214}],"exchange":"NASDAQ","name":"Aerovate Therapeutics, Inc.","nameEN":"Aerovate Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Aerovate Therapeutics, Inc.(AVTE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Aerovate Therapeutics, Inc.(AVTE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Aerovate Therapeutics, Inc.,AVTE,Aerovate Therapeutics, Inc.股票,Aerovate Therapeutics, Inc.股票老虎,Aerovate Therapeutics, Inc.股票老虎国际,Aerovate Therapeutics, Inc.行情,Aerovate Therapeutics, Inc.股票行情,Aerovate Therapeutics, Inc.股价,Aerovate Therapeutics, Inc.股市,Aerovate Therapeutics, Inc.股票价格,Aerovate Therapeutics, Inc.股票交易,Aerovate Therapeutics, Inc.股票购买,Aerovate Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Aerovate Therapeutics, Inc.(AVTE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Aerovate Therapeutics, Inc.(AVTE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}